×

Alkoxy compounds for disease treatment

  • US 10,639,286 B2
  • Filed: 07/23/2018
  • Issued: 05/05/2020
  • Est. Priority Date: 10/05/2007
  • Status: Active Grant
First Claim
Patent Images

1. A method of modulating chromophore flux in a retinoid cycle comprising introducing into a subject a non-retinoid aromatic compound that inhibits 11-cis-retinol production with an IC50 of about 0.1 micromolar or less when assayed in vitro, the assay consisting of a homogenate of HEK293 cell clone expressing recombinant human RPE65 and LRAT as the source of visual enzyme, exogenous all-trans-retinol in the amount of about 20 μ

  • M, recombinant human CRALBP in the amount of about 80 μ

    g/mL, about 10 mM pH 7.2 phosphate buffer, about 0.5% BSA and about 1 mM NaPPi, and wherein the amount of assay reaction product 11-cis-retinol being determined by HPLC analysis following heptane extraction of the assay reaction mixture and wherein the non-retinoid aromatic compound consists of a benzene core that is substituted with a first substituent, a second substituent, and an optional third substituent, wherein the first and second substituents are attached to the benzene core in a meta-substitution configuration, wherein the first substituent is an optionally substituted 3-aminoprop-1-yl group, the second substituent is a (c-C6H11)CH2

    O—

    group, and the optional third substituent is a halogen or —

    OH;

    wherein the optionally substituted 3-aminoprop-1-yl group has the formula —

    C(R9)(R10)C(R1)(R2)CH2NH2,wherein R1 and R2 are each independently selected from hydrogen, halogen, C1-C5 unsubstituted alkyl, or —

    OR6;

    R9 and R19 are each independently selected from hydrogen, halogen, C1-C5 alkyl optionally substituted with hydroxy or halogen, or —

    OR19, andR6, and R19 are each independently hydrogen or CH3.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×